About UNION Therapeutics
UNION Therapeutics is a company based in Hellerup (Denmark) founded in 2013 by Rasmus Vendler Toft-Kehler. UNION Therapeutics has raised $57.06 million across 12 funding rounds from investors including European Commission, European Investment Bank and European Union. The company has 26 employees as of November 30, 2024. UNION Therapeutics offers products and services including Orismilast and Pipeline Drugs. UNION Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, ASLAN Pharmaceuticals, Melinta Therapeutics and Iterum Therapeutics, among others.
- Headquarter Hellerup, Denmark
- Employees 26 as on 30 Nov, 2024
- Founders Rasmus Vendler Toft-Kehler
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Union Therapeutics A/S
-
Annual Revenue
$69.74 K (USD)-18as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$57.06 M (USD)
in 12 rounds
-
Latest Funding Round
$6.89 M (USD), Series B
Jun 30, 2022
-
Investors
European Commission
& 5 more
-
Employee Count
26
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UNION Therapeutics
UNION Therapeutics offers a comprehensive portfolio of products and services, including Orismilast and Pipeline Drugs.
Treatment for psoriasis and immunological conditions in clinical trials.
Develops options for atopic dermatitis and other immune disorders.
Funding Insights of UNION Therapeutics
UNION Therapeutics has successfully raised a total of $57.06M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $6.89 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in UNION Therapeutics
UNION Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include European Commission, European Investment Bank and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Early stage VC firm investing in Denmark
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for UNION Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UNION Therapeutics
Investment portfolio details for UNION Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - UNION Therapeutics
Detailed financials for UNION Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Union Therapeutics Comparisons
Peer comparison for UNION Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of UNION Therapeutics
UNION Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, ASLAN Pharmaceuticals, Melinta Therapeutics and Iterum Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Targeted small molecules are developed for oncology treatments.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of UNION Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Union Therapeutics
Complete news archive for UNION Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UNION Therapeutics
UNION Therapeutics was founded in 2013.
UNION Therapeutics is headquartered in Hellerup, Denmark.
Kim Domela Kjoller is the current CEO of UNION Therapeutics.
UNION Therapeutics is a funded company, having raised a total of $57.06M across 12 funding rounds to date.
As of Nov 30, 2024, the latest employee count at UNION Therapeutics is 26.
Annual revenue of UNION Therapeutics is $69.74K as on Dec 31, 2022.
UNION Therapeutics was founded in 2013 in Hellerup, Denmark, within the biotechnology sector. Small molecule drugs are developed to address antibiotic resistance in treating bacterial infections and associated conditions. The lead candidate, ATx201, serves as a topical treatment for skin infections. Additional programs include ATx202 for topical acne therapy and ATx401 for oral treatment of C. difficile infections. Operations center on advancing these therapies through research and development.
UNION Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and ASLAN Pharmaceuticals.
UNION Therapeutics offers Orismilast and Pipeline Drugs.
UNION Therapeutics has 6 investors. Key investors include European Commission, European Investment Bank, European Union, Innovationsfonden, and ADT Foundation.
The valuation of UNION Therapeutics is $105.68M as of Jun 2020.